Literature DB >> 1333907

Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.

M Monden1, M Sakon, M Gotoh, T Kanai, K Umeshita, K S Wang, M Sakurai, C Kuroda, J Okamura, T Mori.   

Abstract

In the present study, we compared the survival of patients with multi tumor hepatocellular carcinoma (HCC) following their treatment with liver resection versus TAE. A total of 336 HCC patients were treated at Osaka University Hospital between 1980 and 1989. Of these, 140 patients underwent liver resection in the presence or absence of TAE and 173 subjects were treated with TAE alone. Our TAE protocol consisted of 50 mg Adriamycin, 3-5 ml lipiodol, and Gelfoam. The 1-, 3-, and 5-year survival values found for the liver resection group were 87.4%, 66.0%, and 47.4%, respectively, whereas the values calculated for the TAE group were 64.6%, 29.9%, and 15.8%, respectively. The survival of patients in the resection group was clearly better than that of subjects in the TAE group. Of the 140 patients who underwent resection, 36 cases were proven to have multiple lesions by histopathological examination. The 1- and 3-year survival values determined for this special group were 67.9% and 33.3%, respectively. Of the TAE cases, 113 were diagnosed as having multiple lesions by imaging examination, and their 1- and 3-year survival values were 59.7% and 24.9%, respectively. No significant differences in survival was found between these two different treatment modalities for these multiple-lesion cases. The results of this study indicate that it is unlikely that surgical resection is superior to TAE alone for the treatment of HCC patients with multiple lesions.

Entities:  

Mesh:

Year:  1992        PMID: 1333907     DOI: 10.1007/bf00687103

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  40 in total

1.  Segmental and subsegmental resections of the cirrhotic liver under hepatic inflow and outflow occlusion.

Authors:  N Nagasue; H Yukaya; Y Ogawa; S Hirose; M Okita
Journal:  Br J Surg       Date:  1985-07       Impact factor: 6.939

2.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

3.  Malignant tumors of the liver.

Authors:  G C Vitale; L S Heuser; H C Polk
Journal:  Surg Clin North Am       Date:  1986-08       Impact factor: 2.741

4.  Primary malignant tumors of the liver.

Authors:  A A el-Domeiri; A G Huvos; H S Goldsmith; F W Foote
Journal:  Cancer       Date:  1971-01       Impact factor: 6.860

5.  Postoperative prognosis as related to blood ketone body ratios in hepatectomized patients.

Authors:  M Asano; K Ozawa; T Tobe
Journal:  Eur Surg Res       Date:  1983       Impact factor: 1.745

6.  Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas.

Authors:  M Monden; J Okamura; M Sakon; M Gotoh; K Kobayashi; K Umeshita; T Yamada; C Kuroda; M Sakurai; T Mori
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Hepatic resection for hepatocellular carcinoma.

Authors:  T Tsuzuki; A Sugioka; M Ueda; S Iida; T Kanai; H Yoshii; K Nakayasu
Journal:  Surgery       Date:  1990-05       Impact factor: 3.982

8.  Transcatheter chemo-embolization effective for treating hepatocellular carcinoma. A histopathologic study.

Authors:  M Sakurai; J Okamura; C Kuroda
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

9.  Estimation of the functional reserve of human liver.

Authors:  F G Moody; L F Rikkers; J S Aldrete
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969

Review 10.  Surgical management of hepatocellular carcinoma.

Authors:  M T Lotze
Journal:  Gastroenterol Clin North Am       Date:  1987-12       Impact factor: 3.806

View more
  6 in total

Review 1.  Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma.

Authors:  H J Jaeger; U M Mehring; F Castañeda; F Hasse; G Blumhardt; D Loehlein; K D Mathias
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Nov-Dec       Impact factor: 2.740

Review 2.  Combined hepatocholangiocarcinoma: case-series and review of literature.

Authors:  Vishal Bhagat; Milind Javle; Jihnhee Yu; Aarti Agrawal; John F Gibbs; Boris Kuvshinoff; Enriquetta Nava; Renuka Iyer
Journal:  Int J Gastrointest Cancer       Date:  2006

3.  CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE.

Authors:  Jia-Wen Zhang; Xiao-Yuan Feng; Han-Qiu Liu; Zhen-Wei Yao; Yan-Mei Yang; Bin Liu; Yong-Qiang Yu
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

Review 4.  Current treatment modalities for hepatocellular carcinoma.

Authors:  D G Farmer; M H Rosove; A Shaked; R W Busuttil
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

5.  Evaluation of the therapeutic effect of TAE on primary liver cancer.

Authors:  T Yamada; F Makita; K Takehara; S Saitou; K Satou; K Endou; R Shimoda; Y Matsuzaki; T Matsumoto; K Yuasa
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases.

Authors:  T Kanai; M Monden; M Sakon; M Gotoh; K Umeshita; Y Hasuike; H Nakano; T Monden; T Murakami; H Nakamura
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.